Current Cardiology Reviews最新文献

{"title":"Artificial Intelligence Tools in Myocardial Infarction Prognosis: Evaluating the Performance of Machine Learning and Deep Learning Models.","authors":"Cyntia Szymanska, Artur Baszko","doi":"10.2174/011573403X380162250706094642","DOIUrl":"10.2174/011573403X380162250706094642","url":null,"abstract":"<p><p>In clinical practice, mortality risk assessment in patients with myocardial infarction often relies on scales such as GRACE and TIMI. However, these scales were developed based on cohorts assembled many years ago. Since then, numerous changes have occurred, ranging from shifts in MI patient profiles to the introduction of new antiplatelet medications and the adoption of more restrictive lipid therapy targets. To address this issue, researchers are working to develop new stratification tools. Artificial intelligence (AI), which finds applications in nearly every area of medicine, also presents solutions to this problem. This review includes sixteen papers that contain machine learning and deep learning models used to prognosticate mortality risk at different points. Machine learning (ML) models, such as random forest, gradient boosting, and support vector machines, have demonstrated good to excellent performance. However, no single algorithm appears to be top-performing. Although artificial neural networks are considered one of the most promising algorithms, they do not invariably outperform other ML methods. The adaptability of AI models to various scenarios and their ability to handle complex datasets reassures us of their potential in cardiology. Concerning variables that influence the risk of mortality, most are well-established factors, such as age, left-ventricular ejection fraction, lipid parameters, and B-type natriuretic peptide. Additionally, less apparent indicators include platelet parameters, neutrophil count, and blood urea nitrogen. In conclusion, utilizing AI-based models in myocardial infarction risk stratification presents a significant opportunity to develop effective and tailored tools.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X380162"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-myocardial Infarction Prognostic Factors and Mortality in the Gulf Region: A Systematic Review and Meta-analysis.","authors":"Demah Alsalman, Arwa Alumran, Nida Aslam, Mohammed Almansori","doi":"10.2174/011573403X404850251128170941","DOIUrl":"10.2174/011573403X404850251128170941","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular disease is a leading cause of mortality in the Gulf region, with acute Myocardial Infarction (MI) being a critical contributor due to prevalent comorbidities, including diabetes, hypertension, and obesity. This systematic review and meta-analysis evaluate the prognostic factors impacting post-MI outcomes.</p><p><strong>Methods: </strong>This study conducted a systematic review and meta-analysis to identify risk factors influencing Myocardial Infarction (MI) outcomes in Saudi Arabia and Gulf countries. A comprehensive search of major databases between 2013 and 2024 included studies examining demographic and clinical predictors such as age, gender, and comorbidities. Eligible studies were screened following PRISMA guidelines. Adjusted odds ratios for mortality were pooled, and heterogeneity was assessed through Q and I² statistics. Bias and publication bias were evaluated using ROBINS-I and funnel plots, respectively. Analyses were performed to provide regionspecific insights into MI prognosis and outcome predictors.</p><p><strong>Results: </strong>The findings reveal that gender, age, comorbidities, and biomarkers significantly influence mortality risks. Women presented higher mortality rates than men, attributed to older age and a heavier comorbidity burden. Ventricular arrhythmias and recurrent MI emerged as predictors of adverse in-hospital outcomes, including heart failure and cardiogenic shock. The pooled odds ratio for short-term mortality indicated over three times the mortality risk following MI, although long-term mortality findings lacked statistical significance.</p><p><strong>Discussion: </strong>The findings highlight the combined impact of demographic and clinical factors on MI outcomes in the Gulf region. The gender disparity reflects both biological and systemic influences.</p><p><strong>Conclusion: </strong>Tailored interventions, improved risk stratification, and targeted management strategies are needed to address the high-risk profiles and outcome disparities in Gulf MI patients.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X404850"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Retrospective Cohort Analysis of Sex - Specific Cardiovascular Outcomes.","authors":"Ramzi Ibrahim, Rahmeh Al-Asmar, Hashim AlHammouri, Mahmoud Abdelnabi, Beani Forst, Hoang Nhat Pham, Patrick Sarkis, Steven J Lester, Chadi Ayoub, Kwan Lee, Julie Rosenthal, Reza Arsanjani","doi":"10.2174/011573403X394902250911111958","DOIUrl":"10.2174/011573403X394902250911111958","url":null,"abstract":"<p><strong>Introduction: </strong>Sex-based differences in outcomes among patients with heart failure with reduced ejection fraction (HFrEF) treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain underexplored. This study aimed to evaluate sex-specific differences in cardiovascular outcomes in patients with HFrEF receiving SGLT2 inhibitors alongside guidelinedirected medical therapy (GDMT).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the TriNetX global research network. Adults with HFrEF treated with SGLT2is and GDMT were stratified by sex. Propensity score matching (PSM) was used to balance baseline demographics, comorbidities, medications, and laboratory data. Primary outcomes were all-cause mortality and acute heart failure (HF) events; secondary outcomes included hospitalizations, arrhythmias, renal outcomes, and advanced therapies.</p><p><strong>Results: </strong>After PSM, 17,408 male and 17,408 female patients were analyzed. Male patients had lower odds of acute HF events (aOR: 0.949; 95% CI: 0.909-0.991), all-cause hospitalizations (aOR: 0.933; 95% CI: 0.895-0.973), and renal failure (aOR: 0.915; 95% CI: 0.870-0.962). No significant differences were observed in all-cause mortality (aOR: 1.003; 95% CI: 0.926-1.087) or heart transplantation, although LVAD use was more frequent in males (aOR: 1.416; 95% CI: 1.053-1.905).</p><p><strong>Discussion: </strong>The findings highlighted potential sex-based disparities in outcomes for patients with HFrEF on SGLT2is. Differential prescribing patterns, comorbidity burden, or timing of therapy initiation may contribute to observed differences.</p><p><strong>Conclusion: </strong>Among HFrEF patients treated with SGLT2is, males experienced lower risks of HF events, hospitalizations, and renal failure compared to females, despite similar mortality. Further research is needed to understand and address sex-specific disparities in HFrEF management.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X394902"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Repair and Mesenchymal Stem Cells: Exploring New Frontiers in Regenerative Medicine.","authors":"Sadia Nazir, Tahir Maqbool, Sumeyra Savas","doi":"10.2174/011573403X376065250728094646","DOIUrl":"10.2174/011573403X376065250728094646","url":null,"abstract":"<p><p>Cardiovascular diseases, especially myocardial infarction, remain the prominent causes of death globally, necessitating the exploration of innovative therapeutic strategies. Medical and surgical available treatments mainly manage disease symptoms and prevent deterioration, but do not focus on the repair of lost cardiomyocytes. Mesenchymal stem cells (MSCs) have emerged as a promising tool for heart repair and regeneration after injury, as they possess unique properties, such as the potential for differentiation into cardiomyocytes and vascular endothelial cells, immunomodulation, the release of mediators, and paracrine effects. This review focuses on the latest understanding of MSC therapies for cardiac repair, specifically addressing their properties, mechanism of action, preclinical and clinical studies, problems and prospects, and future strategies. MSCs can be isolated from various tissues, including bone marrow and adipose tissue, each with its own advantages and disadvantages in cardiac repair. Many preclinical studies conducted concluded that MSCs could differentiate into cardiomyocytes. MSCs involve multiple factors that enhance angiogenesis, promote the survival of existing myocardium and cardiomyocytes, reduce fibrosis, modulate the immune response, activate existing cardiac stem cells, and facilitate tissue remodeling; all of these processes are crucial in myocardial repair after MI. Although preclinical studies have promising outcomes, the application of MSC therapy in clinical trials has faced many challenges. Clinical trials conducted so far have yielded variable outcomes, with some showing marked improvements and others producing no promising results, indicating less improvement in cardiac function and mortality. This variability may be due to multiple sources, including MSCs, delivery methods, culture conditions, the timing of administration after MI, and patient-dependent factors, such as disease severity, overall patient well-being, and other comorbid conditions. The review concluded that although MSCs have a significant role in cardiac repair, further research is essential for overcoming current challenges to unlocking the maximum regenerative potential of these cells.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X376065"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13273749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of eRNAs in Cardiovascular Diseases.","authors":"Yuqing Li, Chao Song, Jian Cui, XiangYu Fei, XiaoYong Lei, Huifang Tang","doi":"10.2174/011573403X375542250529182602","DOIUrl":"10.2174/011573403X375542250529182602","url":null,"abstract":"<p><p>Enhancer RNAs (eRNAs), a class of non-coding RNAs transcribed from enhancer regions, have emerged as critical regulators of gene expression in cardiovascular diseases (CVDs), which are among the leading causes of morbidity and mortality in China. The pathogenesis of CVD is complex, involving precise regulation of diverse biological processes. Recent advances in epigenetics have highlighted the pivotal role of eRNAs in gene regulation. This review summarizes the fundamental characteristics of eRNAs and their mechanisms of action in CVD, focusing on how they regulate gene expression through enhancer-promoter looping, chromatin remodeling, and transcriptional control. Key eRNAs, including IRENES, CARMEN, LINC00607, HERNA1, PSMB8-AS1, and WISPER, are discussed in detail, emphasizing their roles in pathological processes, such as cardiac development, vascular remodeling, atherosclerosis, and fibrosis. These eRNAs interact with transcription factors and others to influence cardiovascular gene regulatory networks. Advances in high-throughput sequencing have identified eRNAs as potential biomarkers and therapeutic targets in CVDs, offering implications for diagnosis, treatment, and precision medicine. For instance, targeting CARMEN may attenuate atherosclerosis, while LEENE could address endothelial dysfunction. Despite their therapeutic potential, further studies are needed to elucidate the mechanisms underlying eRNAs function and their roles in CVD pathogenesis. A deeper understanding of eRNAs may pave the way for novel therapeutic strategies in cardiovascular medicine.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X375542"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Foundation and Novel Insights of Resveratrol in Cardiovascular System: A Review.","authors":"Ruchi Tiwari, Gaurav Tiwari, Anju Singh, Namdev Dhas","doi":"10.2174/011573403X343252250502045328","DOIUrl":"10.2174/011573403X343252250502045328","url":null,"abstract":"<p><p>Research into drugs that can enhance cardiovascular health has been sparked by the rising prevalence of cardiovascular illnesses (CVDs). In addition to its anti-inflammatory and antioxidant qualities, Resveratrol (RES) is well known for its capacity to increase endothelial NO synthase (eNOS) activity. This page summarises RES's wide effects on energy metabolism, resilience to stress, exercise mimicking, circadian rhythm, lifespan control, and microbiome composition. This article addresses the poor and contradictory results shown in preclinical and clinical trials provides an update on the cardiovascular preventive properties of RES. The activation of AMP-activated protein kinase (AMPK), silent information regulator 1 (SIRT1), and natural antioxidant enzymes is associated with some of the positive effects of RES on the cardiovascular system. A microarray data summary indicates a strong correlation between the heart's reaction to calorie restriction and the transcriptional responses to RES. RES has been demonstrated to reduce contractile dysfunction, cardiac remodelling, and hypertrophy in several animal models of heart failure. Its preventive properties are believed to be due to several molecular pathways, including the suppression of prohypertrophic signalling molecules, enhancement of cardiac Ca²⁺ handling, control of autophagy, and decreases in inflammation. RES thus has the potential to be used in several novel therapeutic approaches for treating diseases such as atherosclerosis, ischemia/reperfusion damage, metabolic syndrome, heart failure, and inflammatory changes associated with ageing.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X343252"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote ECG-guided Cardiac Rehabilitation: An Outpatient Model Using the Accordix Platform.","authors":"Irina E Mishina, Ksenia A Blinova, Anton A Gudukhin, Elena N Kopysheva","doi":"10.2174/011573403X413907251120143344","DOIUrl":"10.2174/011573403X413907251120143344","url":null,"abstract":"<p><p>Telemedicine-based cardiac rehabilitation (CR) offers a viable and accessible alternative to traditional center-based programs, leveraging remote monitoring and individualized exercise prescriptions to improve cardiovascular health in patients post-acute myocardial infarction. This overview examines the implementation of the \"Accordix\" system, a telemedicine platform utilized for outpatient CR. The \"Accordix\" system facilitates real-time ECG monitoring and communication between patients and a multidisciplinary rehabilitation team. Patients undergo an initial in-person assessment to determine individual exercise parameters, followed by home-based exercise sessions supported by the system's feedback mechanisms (e.g., heart rate alerts and Borg scale integration). The platform allows physicians to remotely monitor patient progress, adjust treatment plans, and address potential adverse events, thus enabling a hybrid CR approach that combines the benefits of in-person and remote care. Future directions include integrating video consultations to enhance guidance on exercise technique and expanding accessibility to underserved populations. The focus is on improving patient training protocols to ensure proper device use, self-monitoring skills, and adherence to exercise guidelines. Telemedicine- based CR, exemplified by the \"Accordix\" system, holds significant promise for improving access to cardiac rehabilitation, optimizing treatment outcomes, empowering patients through self-management, and promoting long-term adherence to lifestyle changes. Further research and implementation efforts are warranted to fully realize the potential of this approach in reducing the burden of cardiovascular disease.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X413907"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Cancer: An Evidence-Based Study of Occurrence.","authors":"Zahra Tolou-Ghamari","doi":"10.2174/011573403X349291250716112053","DOIUrl":"10.2174/011573403X349291250716112053","url":null,"abstract":"<p><strong>Introduction: </strong>From 1931 to 2025, spanning 94 years, cardiac cancer has remained a rare and sporadic tumor that poses both an investigative dilemma and a therapeutic challenge. Autopsy findings indicate that the incidence of primary cardiac malignancies is approximately 0.02 percent. Surgical resection is considered a viable and often successful treatment option.</p><p><strong>Aims: </strong>The present study aims to provide an overall assessment of cardiac cancer in Isfahan Province, Iran.</p><p><strong>Objectives: </strong>To provide detailed information on specific aspects, such as frequency and demographic characteristics of cardiac cancer.</p><p><strong>Methods: </strong>The representative data of this study were drawn from the general population of Isfahan Province. SEER (Surveillance, Epidemiology, and End Results) data were obtained from the Deputy of Health, Division of Registry of Cancer (between 2011 and 2015). With attention to subject selection (the authors followed the Sex and Gender Equity in Research (SAGER) Guidelines), and according to the ICDO topography code, C38 was considered for further investigation as heart cancer or cardiac tumors.</p><p><strong>Results and discussion: </strong>During the study period, a total of 30,465 cancer patients were recorded, comprising 14,638 females and 15,827 males. Among these, 122 cases (0.4 percent) were identified as cardiac cancer, including 42 females and 80 males. The patients' ages ranged from 3 to 95 years, with a mean age of 46.8 ± 21.5 years. The annual distribution of reported cardiac tumors during the study period was as follows: 34, 37, 18, and 33 cases, respectively. Based on available data from the monographic code M, which does not specify subtypes, the following conditions were recorded: mesothelioma (n = 25), neoplasm (n = 11), Hodgkin lymphoma, nodular sclerosis, NOS (n = 14), and other unspecified conditions. A total of three deaths were reported.</p><p><strong>Conclusion: </strong>In the population studied, the frequency of cardiac cancer in men was significantly higher than in women. Age related to cardiac cancer in 51% was between 40-70 years old. For the patient satisfaction and financial aspects of the Iranian health system, further consideration is suggested regarding referral systems, evidence-based pharmacotherapy, and post-surgery outcome inquiries.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X349291"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial Dysfunction in Cardiac Diseases: Insights into Pathophysiology and Clinical Outcomes.","authors":"Syed Shadab Ahmad, Javed Akhtar Ansari, Tarique Mahmood Ansari, Syed Mehdi Hasan Zaidi","doi":"10.2174/011573403X379197250417061904","DOIUrl":"10.2174/011573403X379197250417061904","url":null,"abstract":"<p><p>Mitochondrial dysfunction plays a crucial role in the pathogenesis of various cardiac diseases, including heart failure, ischemic cardiomyopathy, and drug-induced cardiotoxicity. Mitochondria are essential for cellular energy production, calcium homeostasis, redox balance, and apoptotic regulation, making their proper function vital for cardiac health. Dysfunctional mitochondria contribute to excessive reactive oxygen species (ROS) production, impaired ATP synthesis, and disruption of mitochondrial dynamics, leading to cardiomyocyte damage and cell death. Emerging research highlights mitochondrial dynamics, including fission, fusion, mitophagy, and biogenesis, as critical determinants of cardiac homeostasis. Perturbations in these processes exacerbate myocardial injury and heart failure progression. Additionally, chemotherapy-induced cardiotoxicity, primarily from anthracyclines, is closely linked to mitochondrial damage, underscoring the need for targeted therapeutic strategies. Pharmacological interventions, such as antioxidants, mitochondrial-targeted drugs, and cardioprotective agents, have shown promise in mitigating mitochondrial dysfunction-related cardiac toxicity. Furthermore, lifestyle modifications, including exercise and dietary interventions, are being explored to enhance mitochondrial resilience in cardiac tissues. Advanced imaging techniques and biomarker-based diagnostics are improving the early detection of mitochondrial dysfunction in cardiac diseases. Emerging therapeutic strategies, such as mitochondrial transplantation, gene therapy, and precision medicine approaches, hold potential for targeted intervention. Despite these advances, challenges remain in translating mitochondrial-targeted therapies into clinical practice due to complexities in mitochondrial regulation and inter-organ communication. Future research should focus on optimizing mitochondrial-targeted interventions, improving diagnostic precision, and exploring novel molecular pathways to mitigate cardiac mitochondrial dysfunction. A comprehensive understanding of mitochondrial pathophysiology in cardiac diseases will pave the way for innovative treatment strategies aimed at preserving cardiac function and reducing the burden of heart failure.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X379197"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Emerging Roles of Resolvins: Potential Diagnostic Biomarkers for Cardiovascular Diseases.","authors":"Reyhan Bolat, Burak Yazgan","doi":"10.2174/011573403X370785250417015007","DOIUrl":"10.2174/011573403X370785250417015007","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) are the leading cause of death worldwide and include a range of conditions affecting the heart and vascular system. There is a growing priority on identifying and validating biomarkers for CVDs to increase early diagnosis and survival rates. Within this framework of research, there has been a notable increase in interest in resolvins, a class of specialized pro-resolving mediators. Resolvins are well-known for their capacity to promote tissue healing and reduce inflammation. They are categorized into three series: Dseries (RvD1 to RvD6), T-series (RvT1 to RvT4), and E-series (RvE1 to RvE4). These molecules are produced through biochemical pathways involving enzymes such as lipoxygenase (LOX), cyclooxygenase (COX), and cytochrome P450 (CYP). These enzymes utilize precursor molecules like docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and docosapentaenoic acid (DPA). This review addresses a critical gap in the literature by evaluating the potential of resolvins as biomarkers for the diagnosis and prognosis of cardiovascular diseases. By synthesizing existing knowledge on their production pathways and receptors, it highlights the implications of altered resolvins levels in disease mechanisms and offers new perspectives on their clinical relevance.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X370785"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}